PALI - Palisade Bio, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$4.50
DETAILS
HIGH:
$7.00
LOW:
$2.00
MEDIAN:
$4.50
CONSENSUS:
$4.50
UPSIDE:
119.51%
About Palisade Bio, Inc. (https://www.palisadebio.com)
Palisade Bio, Inc. is a clinical-stage biopharmaceutical firm dedicated to identifying, advancing, and bringing to market orally administered treatments for significant conditions stemming from a compromised gastrointestinal mucosal barrier. The company's primary therapeutic candidate, LB1148, is an oral liquid formulation designed to inhibit digestive enzymes. Its goal is to safeguard gut integrity when the intestine experiences stress due to factors such as diminished blood supply, infections, or surgical procedures. Established in 2005, the company maintains its headquarters in Carlsbad, California.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| J. D. Finley | Chief Executive Officer, Chief Financial Officer & Director | 1958 | $1,006,300 USD |
| Mitchell Lawrence Jones | President & Chief Medical Officer | 1977 | $704,000 USD |
| Adarsh Patel | Head of Chemistry, Manufacturing & Controls | – | – |
| Daniel J. Larkins | Head of Global Regulatory Affairs | – | – |
| Dawn Louro | VP & Head of Clinical Operations | – | – |
| James Izanec | VP & Head of Clinical Development | – | – |
| Joerg Heyer | Head of Translational Science & Medicine | – | – |
| Ramesh C. Donthamsetty | Head of Corporate Development & Investor Relations | – | – |
| Ryker Willie | Senior Vice President of Finance & Corporate Controller | – | – |
| Sharon Skare | Vice President & Global Head of Clinical Operations | – | – |